Jad Chahoud, Medical Director of IPOP and Associate Member of the Department of Genitourinary Oncology at Moffitt Cancer Center, shared a post on LinkedIn:
“Big step forward in TNBC.
Early results from TROPION-Breast02 show Datroway (datopotamab deruxtecan) improved overall survival and progression-free survival vs chemotherapy in 1L metastatic triple-negative breast cancer patients ineligible for immunotherapy.
If confirmed, this could redefine care for many mTNBC patients!
Excited to see the full data at ESMO25!”
More posts featuring Jad Chahoud.